Guangdong Jiaying Pharmaceutical Co Ltd
Guangdong Jiaying Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines in Mainland China. The company offers medicines primarily for the treatment of throat, cold, orthopedics, rheumatism, gynecology, heat-clearing, tonic, and gastrointestinal diseases. It also provides Shuangliao Houfeng powder, Chongganling tablets, Jiegu Qili tablet… Read more
Guangdong Jiaying Pharmaceutical Co Ltd (002198) - Net Assets
Latest net assets as of September 2025: CN¥709.01 Million CNY
Based on the latest financial reports, Guangdong Jiaying Pharmaceutical Co Ltd (002198) has net assets worth CN¥709.01 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥774.73 Million) and total liabilities (CN¥65.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥709.01 Million |
| % of Total Assets | 91.52% |
| Annual Growth Rate | 14.68% |
| 5-Year Change | 11.01% |
| 10-Year Change | -18.44% |
| Growth Volatility | 52.36 |
Guangdong Jiaying Pharmaceutical Co Ltd - Net Assets Trend (2004–2024)
This chart illustrates how Guangdong Jiaying Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Guangdong Jiaying Pharmaceutical Co Ltd (2004–2024)
The table below shows the annual net assets of Guangdong Jiaying Pharmaceutical Co Ltd from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥758.22 Million | -0.62% |
| 2023-12-31 | CN¥762.98 Million | +4.75% |
| 2022-12-31 | CN¥728.42 Million | +6.42% |
| 2021-12-31 | CN¥684.48 Million | +0.22% |
| 2020-12-31 | CN¥683.01 Million | +2.99% |
| 2019-12-31 | CN¥663.17 Million | -15.56% |
| 2018-12-31 | CN¥785.35 Million | +4.74% |
| 2017-12-31 | CN¥749.81 Million | -23.87% |
| 2016-12-31 | CN¥984.87 Million | +5.93% |
| 2015-12-31 | CN¥929.70 Million | +7.69% |
| 2014-12-31 | CN¥863.35 Million | +6.63% |
| 2013-12-31 | CN¥809.66 Million | +191.16% |
| 2012-12-31 | CN¥278.08 Million | +2.80% |
| 2011-12-31 | CN¥270.51 Million | +4.66% |
| 2010-12-31 | CN¥258.47 Million | +7.06% |
| 2009-12-31 | CN¥241.42 Million | +6.66% |
| 2008-12-31 | CN¥226.35 Million | +6.45% |
| 2007-12-31 | CN¥212.62 Million | +157.33% |
| 2006-12-31 | CN¥82.63 Million | +28.32% |
| 2005-12-31 | CN¥64.39 Million | +31.49% |
| 2004-12-31 | CN¥48.97 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Guangdong Jiaying Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3256.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥99.29 Million | 13.10% |
| Common Stock | CN¥507.51 Million | 66.93% |
| Other Comprehensive Income | CN¥27.77 Million | 3.66% |
| Other Components | CN¥123.65 Million | 16.31% |
| Total Equity | CN¥758.22 Million | 100.00% |
Guangdong Jiaying Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Guangdong Jiaying Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guangdong LingXiao Pump Industry Co Ltd
SHE:002884
|
$447.71 Million |
|
Qingdao Doublestar Co Ltd
SHE:000599
|
$447.80 Million |
|
Alembic Pharmaceuticals Limited
NSE:APLLTD
|
$447.90 Million |
|
SFTCF
PINK:SFTCF
|
$447.95 Million |
|
MilDef Group AB
ST:MILDEF
|
$447.60 Million |
|
Molymet
SN:MOLYMET
|
$447.57 Million |
|
Honasa Consumer Limited
NSE:HONASA
|
$447.54 Million |
|
DOMS Industries Limited
NSE:DOMS
|
$447.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Guangdong Jiaying Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 762,984,647 to 758,220,755, a change of -4,763,892 (-0.6%).
- Net income of 20,611,599 contributed positively to equity growth.
- Dividend payments of 25,401,080 reduced retained earnings.
- Other comprehensive income increased equity by 544,446.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥20.61 Million | +2.72% |
| Dividends Paid | CN¥25.40 Million | -3.35% |
| Other Comprehensive Income | CN¥544.45K | +0.07% |
| Other Changes | CN¥-518.86K | -0.07% |
| Total Change | CN¥- | -0.62% |
Book Value vs Market Value Analysis
This analysis compares Guangdong Jiaying Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.22x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 44.05x to 5.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | CN¥0.18 | CN¥7.79 | x |
| 2005-12-31 | CN¥0.21 | CN¥7.79 | x |
| 2006-12-31 | CN¥0.27 | CN¥7.79 | x |
| 2007-12-31 | CN¥0.70 | CN¥7.79 | x |
| 2008-12-31 | CN¥0.56 | CN¥7.79 | x |
| 2009-12-31 | CN¥0.58 | CN¥7.79 | x |
| 2010-12-31 | CN¥0.63 | CN¥7.79 | x |
| 2011-12-31 | CN¥0.66 | CN¥7.79 | x |
| 2012-12-31 | CN¥0.68 | CN¥7.79 | x |
| 2013-12-31 | CN¥1.90 | CN¥7.79 | x |
| 2014-12-31 | CN¥1.70 | CN¥7.79 | x |
| 2015-12-31 | CN¥1.83 | CN¥7.79 | x |
| 2016-12-31 | CN¥1.94 | CN¥7.79 | x |
| 2017-12-31 | CN¥1.48 | CN¥7.79 | x |
| 2018-12-31 | CN¥1.55 | CN¥7.79 | x |
| 2019-12-31 | CN¥1.31 | CN¥7.79 | x |
| 2020-12-31 | CN¥1.35 | CN¥7.79 | x |
| 2021-12-31 | CN¥1.35 | CN¥7.79 | x |
| 2022-12-31 | CN¥1.44 | CN¥7.79 | x |
| 2023-12-31 | CN¥1.50 | CN¥7.79 | x |
| 2024-12-31 | CN¥1.49 | CN¥7.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Guangdong Jiaying Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.48%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.11x
- Recent ROE (2.72%) is below the historical average (5.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 5.65% | 7.39% | 0.52x | 1.47x | CN¥-2.13 Million |
| 2005 | 23.95% | 28.37% | 0.60x | 1.42x | CN¥8.98 Million |
| 2006 | 26.76% | 35.28% | 0.52x | 1.45x | CN¥13.85 Million |
| 2007 | 11.48% | 37.81% | 0.26x | 1.15x | CN¥3.16 Million |
| 2008 | 6.06% | 20.68% | 0.28x | 1.04x | CN¥-8.91 Million |
| 2009 | 6.25% | 24.19% | 0.25x | 1.05x | CN¥-9.06 Million |
| 2010 | 9.77% | 33.55% | 0.25x | 1.16x | CN¥-600.14K |
| 2011 | 7.48% | 23.56% | 0.28x | 1.13x | CN¥-6.81 Million |
| 2012 | 2.72% | 7.24% | 0.33x | 1.13x | CN¥-20.24 Million |
| 2013 | 17.23% | 61.52% | 0.25x | 1.14x | CN¥58.52 Million |
| 2014 | 8.53% | 13.02% | 0.55x | 1.20x | CN¥-12.68 Million |
| 2015 | 7.14% | 13.95% | 0.45x | 1.13x | CN¥-26.62 Million |
| 2016 | 5.60% | 12.26% | 0.41x | 1.12x | CN¥-43.32 Million |
| 2017 | -28.64% | -45.88% | 0.53x | 1.17x | CN¥-289.74 Million |
| 2018 | 4.57% | 6.68% | 0.60x | 1.13x | CN¥-42.66 Million |
| 2019 | -18.42% | -24.41% | 0.58x | 1.29x | CN¥-188.50 Million |
| 2020 | 2.90% | 3.64% | 0.67x | 1.18x | CN¥-48.46 Million |
| 2021 | 0.22% | 0.26% | 0.71x | 1.18x | CN¥-66.97 Million |
| 2022 | 6.03% | 6.66% | 0.78x | 1.16x | CN¥-28.91 Million |
| 2023 | 4.50% | 6.44% | 0.63x | 1.11x | CN¥-41.98 Million |
| 2024 | 2.72% | 5.48% | 0.45x | 1.11x | CN¥-55.21 Million |
Industry Comparison
This section compares Guangdong Jiaying Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $856,931,208
- Average return on equity (ROE) among peers: 7.43%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Guangdong Jiaying Pharmaceutical Co Ltd (002198) | CN¥709.01 Million | 5.65% | 0.09x | $447.60 Million |
| Zhejiang Int'L Group Co Ltd (000411) | $189.44 Million | 3.08% | 4.33x | $199.04 Million |
| Zhejiang Zhenyuan Share Co Ltd (000705) | $485.74 Million | 1.60% | 0.77x | $307.06 Million |
| Hunan Jingfeng Pharmaceutical (000908) | $336.40 Million | 0.81% | 1.44x | $202.85 Million |
| Hubei Guangji Pharmaceutical Co Ltd (000952) | $1.49 Billion | 3.37% | 0.66x | $229.65 Million |
| Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) | $1.25 Billion | 8.38% | 0.07x | $144.69 Million |
| Yifan Xinfu Pharmaceutical Co Ltd (002019) | $507.64 Million | 23.17% | 1.09x | $1.01 Billion |
| Chongqing Lummy Pharmaceutical (300006) | $1.88 Billion | -4.66% | 0.52x | $475.43 Million |
| Zhejiang Jolly Pharmaceutical Co Ltd (300181) | $1.39 Billion | 1.50% | 0.52x | $1.19 Billion |
| Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) | $181.38 Million | 29.65% | 0.05x | $893.83 Million |